218 related articles for article (PubMed ID: 27299299)
1. Mathematical modeling of erythrocyte chimerism informs genetic intervention strategies for sickle cell disease.
Altrock PM; Brendel C; Renella R; Orkin SH; Williams DA; Michor F
Am J Hematol; 2016 Sep; 91(9):931-7. PubMed ID: 27299299
[TBL] [Abstract][Full Text] [Related]
2. Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.
Park SH; Lee CM; Dever DP; Davis TH; Camarena J; Srifa W; Zhang Y; Paikari A; Chang AK; Porteus MH; Sheehan VA; Bao G
Nucleic Acids Res; 2019 Sep; 47(15):7955-7972. PubMed ID: 31147717
[TBL] [Abstract][Full Text] [Related]
3. Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
Kean LS; Manci EA; Perry J; Balkan C; Coley S; Holtzclaw D; Adams AB; Larsen CP; Hsu LL; Archer DR
Blood; 2003 Dec; 102(13):4582-93. PubMed ID: 12933586
[TBL] [Abstract][Full Text] [Related]
4. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Brendel C; Guda S; Renella R; Bauer DE; Canver MC; Kim YJ; Heeney MM; Klatt D; Fogel J; Milsom MD; Orkin SH; Gregory RI; Williams DA
J Clin Invest; 2016 Oct; 126(10):3868-3878. PubMed ID: 27599293
[TBL] [Abstract][Full Text] [Related]
5. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
Wen J; Tao W; Hao S; Zu Y
J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
[TBL] [Abstract][Full Text] [Related]
6. Gene replacement therapy for sickle cell disease and other blood disorders.
Townes TM
Hematology Am Soc Hematol Educ Program; 2008; ():193-6. PubMed ID: 19074080
[TBL] [Abstract][Full Text] [Related]
7. A novel human gamma-globin gene vector for genetic correction of sickle cell anemia in a humanized sickle mouse model: critical determinants for successful correction.
Perumbeti A; Higashimoto T; Urbinati F; Franco R; Meiselman HJ; Witte D; Malik P
Blood; 2009 Aug; 114(6):1174-85. PubMed ID: 19474450
[TBL] [Abstract][Full Text] [Related]
8. Effects of mixed hematopoietic chimerism in a mouse model of bone marrow transplantation for sickle cell anemia.
Iannone R; Luznik L; Engstrom LW; Tennessee SL; Askin FB; Casella JF; Kickler TS; Goodman SN; Hawkins AL; Griffin CA; Noffsinger L; Fuchs EJ
Blood; 2001 Jun; 97(12):3960-5. PubMed ID: 11389040
[TBL] [Abstract][Full Text] [Related]
9. A systems pharmacology model for gene therapy in sickle cell disease.
Zheng B; Wille L; Peppel K; Hagen D; Matteson A; Ahlers J; Schaff J; Hua F; Yuraszeck T; Cobbina E; Apgar JF; Burke JM; Roberts J; Das R
CPT Pharmacometrics Syst Pharmacol; 2021 Jul; 10(7):696-708. PubMed ID: 34139105
[TBL] [Abstract][Full Text] [Related]
10. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells.
Oh IH; Fabry ME; Humphries RK; Pawliuk R; Leboulch P; Hoffman R; Nagel RL; Eaves C
Exp Hematol; 2004 May; 32(5):461-9. PubMed ID: 15145214
[TBL] [Abstract][Full Text] [Related]
11. At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.
Fitzhugh CD; Cordes S; Taylor T; Coles W; Roskom K; Link M; Hsieh MM; Tisdale JF
Blood; 2017 Oct; 130(17):1946-1948. PubMed ID: 28887325
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of murine sickle cell disease by nonablative conditioning and γ-globin gene-corrected bone marrow cells.
Pestina TI; Hargrove PW; Zhao H; Mead PE; Smeltzer MP; Weiss MJ; Wilber A; Persons DA
Mol Ther Methods Clin Dev; 2015; 2():15045. PubMed ID: 26665131
[TBL] [Abstract][Full Text] [Related]
13. In Vivo HSC Gene Therapy Using a Bi-modular HDAd5/35++ Vector Cures Sickle Cell Disease in a Mouse Model.
Li C; Wang H; Georgakopoulou A; Gil S; Yannaki E; Lieber A
Mol Ther; 2021 Feb; 29(2):822-837. PubMed ID: 32949495
[TBL] [Abstract][Full Text] [Related]
14. Genetic strategies for the treatment of sickle cell anaemia.
Mansilla-Soto J; Rivière I; Sadelain M
Br J Haematol; 2011 Sep; 154(6):715-27. PubMed ID: 21707580
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical Development of a Lentiviral Vector Expressing the Anti-sickling βAS3 Globin for Gene Therapy for Sickle Cell Disease.
Poletti V; Urbinati F; Charrier S; Corre G; Hollis RP; Campo Fernandez B; Martin S; Rothe M; Schambach A; Kohn DB; Mavilio F
Mol Ther Methods Clin Dev; 2018 Dec; 11():167-179. PubMed ID: 30533448
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease.
Miller CL; Imren S; Antonchuk J; Kalberer C; Fabry ME; Nagel RL; Humphries RK; Eaves CJ
Mol Ther; 2002 Sep; 6(3):422-8. PubMed ID: 12231180
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy as the New Frontier for Sickle Cell Disease.
Garg H; Tatiossian KJ; Peppel K; Kato GJ; Herzog E
Curr Med Chem; 2022; 29(3):453-466. PubMed ID: 34047257
[TBL] [Abstract][Full Text] [Related]
18. β-Globin sleeping beauty transposon reduces red blood cell sickling in a patient-derived CD34(+)-based in vitro model.
Sjeklocha LM; Wong PY; Belcher JD; Vercellotti GM; Steer CJ
PLoS One; 2013; 8(11):e80403. PubMed ID: 24260386
[TBL] [Abstract][Full Text] [Related]
19. Correction of sickle cell disease in transgenic mouse models by gene therapy.
Pawliuk R; Westerman KA; Fabry ME; Payen E; Tighe R; Bouhassira EE; Acharya SA; Ellis J; London IM; Eaves CJ; Humphries RK; Beuzard Y; Nagel RL; Leboulch P
Science; 2001 Dec; 294(5550):2368-71. PubMed ID: 11743206
[TBL] [Abstract][Full Text] [Related]
20. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
